Vice President of Business Development & Sales, Fulgent Genetics
Search every verified Jakub interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a December 2016 presentation at Cal State LA, Jakub Sram, Vice President of Business Development & Sales at Fulgent Genetics (then Fulgent Genomics), described the company as having "the largest catalog of genetic tests in the world," which he said surpassed the combined offerings of approximately 700 other laboratories. He stated that the global genetic testing market was valued at $3.8 billion in 2015 and projected to grow to $6.7 billion by 2021. Sram characterized Fulgent's approach as "something like a Lego for genetic testing," allowing clinicians to design customizable gene panels. Sram noted that Fulgent went public a few months prior to the talk and operated two main laboratories, one in Temple City, Los Angeles, and another in China, each with 80 to 100 employees. He attributed the company's profitability since 2012 to a "very strong management team" with experience building billion-dollar companies, and to proprietary technology combining next-generation sequencing, diagnostics, IT, and biometrics. Sram added that the company's highly automated platform, including adaptive software, enabled it to sequence about 330 genomes per week and lower costs over time.
“The genetic testing market was about 3.8 billion dollars in 2015 and has grown to about 6.7 billion dollars by 2021, reflecting a healthy growth trajectory globally.”
“At Fulgent, we have probably the largest catalog of genetic tests in the world, surpassing what about 700 other laboratories offer combined.”
“We created something like a Lego for genetic testing, allowing clinicians to design customizable gene panels and receive results within three to four weeks.”
“Our proprietary chemistry and bioinformatics enable us to make genetic testing very affordable, allowing us to be productive and profitable simultaneously.”
“Fulgent started in 2011 and has been profitable since 2012, driven by a strong management team with experience creating billion-dollar companies.”
“Our technology platform combines next-gen sequencing, diagnostics expertise, IT, and biometrics, including software engineers who developed fingerprint scanning technology used in customs.”
“We have a very flexible content catalog with about 18,000 genes and over 400 gene panels, allowing us to build any combination needed for testing.”
“Our capacity is tremendous; we can sequence about 330 genomes a week and offer a broad menu of cancer, cardiology, and neurology tests.”
“Our platform is highly automated from sample extraction to report generation, using adaptive software that speeds up analysis and lowers costs over time.”
“We recently went public and have two main labs, one in Los Angeles and another in China, with about 80 to 100 employees in each location, serving a fast-growing market with tremendous opportunities.”
Jakub Sram, PhD, MBA Vice President Fulgent Genomics December 14, 2016 - Cal State LA Thanks to our Sponsors Bolton ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Jakub.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →